Atectura Breezhaler

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indacaterol acetate, Mometasone furoate

Available from:

Novartis Europharm Limited 

ATC code:

R03AK

INN (International Name):

indacaterol, mometasone

Therapeutic group:

Drugs for obstructive airway diseases,

Therapeutic area:

Asthma

Therapeutic indications:

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Product summary:

Revision: 9

Authorization status:

Authorised

Authorization date:

2020-05-30

Patient Information leaflet

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-10-2023
Public Assessment Report Public Assessment Report Bulgarian 23-06-2020
Patient Information leaflet Patient Information leaflet Spanish 16-10-2023
Public Assessment Report Public Assessment Report Spanish 23-06-2020
Patient Information leaflet Patient Information leaflet Czech 16-10-2023
Public Assessment Report Public Assessment Report Czech 23-06-2020
Patient Information leaflet Patient Information leaflet Danish 16-10-2023
Public Assessment Report Public Assessment Report Danish 23-06-2020
Patient Information leaflet Patient Information leaflet German 16-10-2023
Public Assessment Report Public Assessment Report German 23-06-2020
Patient Information leaflet Patient Information leaflet Estonian 16-10-2023
Public Assessment Report Public Assessment Report Estonian 23-06-2020
Patient Information leaflet Patient Information leaflet Greek 16-10-2023
Public Assessment Report Public Assessment Report Greek 23-06-2020
Patient Information leaflet Patient Information leaflet French 16-10-2023
Public Assessment Report Public Assessment Report French 23-06-2020
Patient Information leaflet Patient Information leaflet Italian 16-10-2023
Public Assessment Report Public Assessment Report Italian 23-06-2020
Patient Information leaflet Patient Information leaflet Latvian 16-10-2023
Public Assessment Report Public Assessment Report Latvian 23-06-2020
Patient Information leaflet Patient Information leaflet Lithuanian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-10-2023
Public Assessment Report Public Assessment Report Lithuanian 23-06-2020
Patient Information leaflet Patient Information leaflet Hungarian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 16-10-2023
Public Assessment Report Public Assessment Report Hungarian 23-06-2020
Patient Information leaflet Patient Information leaflet Maltese 16-10-2023
Public Assessment Report Public Assessment Report Maltese 23-06-2020
Patient Information leaflet Patient Information leaflet Dutch 16-10-2023
Public Assessment Report Public Assessment Report Dutch 23-06-2020
Patient Information leaflet Patient Information leaflet Polish 16-10-2023
Public Assessment Report Public Assessment Report Polish 23-06-2020
Patient Information leaflet Patient Information leaflet Portuguese 16-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 16-10-2023
Public Assessment Report Public Assessment Report Portuguese 23-06-2020
Patient Information leaflet Patient Information leaflet Romanian 16-10-2023
Public Assessment Report Public Assessment Report Romanian 23-06-2020
Patient Information leaflet Patient Information leaflet Slovak 16-10-2023
Public Assessment Report Public Assessment Report Slovak 23-06-2020
Patient Information leaflet Patient Information leaflet Slovenian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 16-10-2023
Public Assessment Report Public Assessment Report Slovenian 23-06-2020
Patient Information leaflet Patient Information leaflet Finnish 16-10-2023
Public Assessment Report Public Assessment Report Finnish 23-06-2020
Patient Information leaflet Patient Information leaflet Swedish 16-10-2023
Public Assessment Report Public Assessment Report Swedish 23-06-2020
Patient Information leaflet Patient Information leaflet Norwegian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 16-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 16-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 16-10-2023
Patient Information leaflet Patient Information leaflet Croatian 16-10-2023
Public Assessment Report Public Assessment Report Croatian 23-06-2020